DRD2 and Parkinson disease: Masellis et al. reported that single nucleotide polymorphisms rs2283265 in the DRD2 were found to be significantly associated with a favorable peak response to rasagiline at 12 weeks in early Parkinson’s disease (Masellis et al. 2016).